EPISODE · Dec 20, 2022 · 19 MIN
Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
from BioCentury This Week · host BioCentury
Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said BioCentury Director of Biopharma Intelligence Paul Bonanos. Bonanos and colleagues discuss what Madrigal got right in running its trial for the challenging NASH indication, and what’s next in the pipeline. BioCentury’s editors also assess highly anticipated, heavily scrutinized data from Moderna among other 4Q22 readouts from neoantigen programs, as well as translational highlights from BioCentury’s Distillery.Reach us by sending a text
What this episode covers
Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said BioCentury Director of Biopharma Intelligence Paul Bonanos. Bonanos and colleagues discuss what Madrigal got right in running its trial for the challenging NASH indication, and what’s next in the pipeline. BioCentury’s editors also assess highly anticipated, heavily scrutinized data from Moderna among other 4Q22 readouts from neoantigen program...
NOW PLAYING
Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m